Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 230

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Clinical next‐generation sequencing in patients with non–small cell lung cancer

Hagemann, Ian S., Devarakonda, Siddhartha, Lockwood, Christina M., Spencer, David H., Guebert, Kalin, Bredemeyer, Andrew J., Al‐Kateb, Hussam, Nguyen, TuDung T., Duncavage, Eric J., Cottrell, Catherine E., Kulkarni, Shashikant, Nagarajan, Rakesh, Seibert, Karen, Baggstrom, Maria, Waqar, Saiama N., Pfeifer, John D., Morgensztern, Daniel, Govindan, Ramaswamy · 2015 · Cancer

Abstract

BACKGROUND: A clinical assay was implemented to perform next‐generation sequencing (NGS) of genes commonly mutated in multiple cancer types. This report describes the feasibility and diagnostic yield of this assay in 381 consecutive patients with non–small cell lung cancer (NSCLC). METHODS: Clinical targeted sequencing of 23 genes was performed with DNA from formalin‐fixed, paraffin‐embedded (FFPE) tumor tissue. The assay used Agilent SureSelect hybrid capture followed by Illumina HiSeq 2000, MiSeq, or HiSeq 2500 sequencing in a College of American Pathologists–accredited, Clinical Laboratory Improvement Amendments–certified laboratory. Single‐nucleotide variants and insertion/deletion events were reported. This assay was performed before methods were developed to detect rearrangements by NGS. RESULTS: Two hundred nine of all requisitioned samples (55%) were successfully sequenced. The most common reason for not performing the sequencing was an insufficient quantity of tissue available in the blocks (29%). Excisional, endoscopic, and core biopsy specimens were sufficient for testing in 95%, 66%, and 40% of the cases, respectively. The median turnaround time (TAT) in the pathology laboratory was 21 days, and there was a trend of an improved TAT with more rapid sequencing platforms. Sequencing yielded a mean coverage of 1318×. Potentially actionable mutations (ie, predictive or prognostic) were identified in 46% of 209 samples and were most commonly found in KRAS (28%), epidermal growth factor receptor (14%), phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha (4%), phosphatase and tensin homolog (1%), and BRAF (1%). Five percent of the samples had multiple actionable mutations. A targeted therapy was instituted on the basis of NGS in 11% of the sequenced patients or in 6% of all patients. CONCLUSIONS: NGS‐based diagnostics are feasible in NSCLC and provide clinically relevant information from readily available FFPE tissue. The sample type is associated with the probability of successful testing. Cancer 2015;121:631–639. © 2014 American Cancer Society.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/cncr.29089

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 230

Metadata

Authors
Hagemann, I. S., Devarakonda, S., Lockwood, C. M., Spencer, D. H., Guebert, K., Bredemeyer, A. J., Al‐Kateb, H., Nguyen, T. T., Duncavage, E. J., Cottrell, C. E., Kulkarni, S., Nagarajan, R., Seibert, K., Baggstrom, M., Waqar, S. N., Pfeifer, J. D., Morgensztern, D., & Govindan, R.
Venue
Cancer
Publisher
Wiley
Published
2014-10-24
Volume
121
Issue
4
Pages
631-639
ISSN
  • 0008-543X (ISSN-L)
  • 1097-0142
OpenAlex
W1539753726
Cited by
230
References
6
FWCI
16.96
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical next‐generation sequencing in patients with non–small cell lung cancer. https://app.cochat.ai/papers/10.1002/cncr.29089
The paper
Hagemann, I. S., Devarakonda, S., Lockwood, C. M., Spencer, D. H., Guebert, K., Bredemeyer, A. J., Al‐Kateb, H., Nguyen, T. T., Duncavage, E. J., Cottrell, C. E., Kulkarni, S., Nagarajan, R., Seibert, K., Baggstrom, M., Waqar, S. N., Pfeifer, J. D., Morgensztern, D., & Govindan, R. (2015). Clinical next‐generation sequencing in patients with non–small cell lung cancer. Cancer. https://doi.org/10.1002/cncr.29089

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.